Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 57, Issue 2, 2013, Pages 155-160

  Shaker, Olfat G ^a   Nassar, Yasser H ^a   Nour, Zeinab A ^a   El Raziky, Mona ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

hepatitis C virus; interleukin 28 B; interleukin 10; pediatrics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EGYPT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMOZYGOTE; HUMAN; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE;

ADOLESCENT; ALLELES; ANTIVIRAL AGENTS; CHILD; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84881025461     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31828febf0     Document Type: Article

References (33)

1. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012;56:527-32.
2. Kamal M. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int 2011;31:45-52.
3. Asselah T, Estrabaud E, Bieche I, et al. HepatitisC: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010;30:1259-69.
4. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
5. Donnelly RP, Sheikh F, Kotenko SV, et al. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004;76:314-21.
6. Brand S, Dambacher J, Beigel F, et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 2007;292:G1019-28.
7. Lio D, Caruso C, Di Stefano R, et al. IL-10 and TNF-a polymorphisms and the recovery from HCV infection. Hum Immunol 2003;64:674-80.
8. Sobue S, Nomura T, Ishikawa T, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001;36:544-51.
9. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
10. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
11. El-Raziky M, El-Hawary M, Esmat G, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol 2007;13:1828-32.
12. Thio C, Gao X, Goedert J, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002;76:4792-7.
13. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/Tat nt-88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43:124-7.
14. Schwarz K, Gonzalez-Peralta R, Murray K, et al. The combination of ribavirin and peg interferon is superior to peg interferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8.
15. Sokal EM, Bourgois A, Stéphenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827-31.
16. Thomas D, Thio C, Martin M, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
17. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
18. Thompson A, Muir A, Sulkowski M, et al. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology 2010;52:2243-4.
19. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons a and g inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-98.
20. Dellgren C, Gad H, Hamming O, et al. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10:125-31.
21. Bouzgarrou N, Hassen E, Farhat K, et al. Combined analysis of interferon-g and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009;70:230-6.
22. Gao Q, Liu D, Zhang S, et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009;15:5610-9.
23. Mangia A. IL28B: A new wager in the skyline of hepatitis C virus infection. Dig Liver Dis 2011;43:177-9.
24. Kusumoto K, Uto H, Hayashi K, et al. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006;34:24-31.
25. Oleksyk T, Thio C, Truelove A, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005;6:347-57.
26. Yee L, Tang J, Gibson A, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-12.
27. Knapp S, Hennig B, Frodsham A, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immu-nogenetics 2003;55:362-9.
28. Dogra G, Chakravarti A, Kar P, et al. Polymorphism of tumor necrosis factor-a and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-a therapy response. Hum Immunol 2011;72:935-9.
29. Afzal M, Tahir S, Salman A, et al. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 2011;5:473-9.
30. Lu Y, Wu X, Huang H, et al. Allele polymorphisms of interleukin-10 and hepatitis B and C virus infection. Chin Med J 2010;23:1338-44.
31. Vidigal P, Germer J, Zein N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and riba-virin. J Hepatol 2002;36:271-7.
32. Chen T, Hsieh Y, Wu T, et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007;150:116-21.
33. Reuss E, Fimmers R, Kruger A, et al. Differential regulation of interleukin-10 production by genetic and environmental factors: a twin study. Genes Immun 2002;3:407-13.